WIDIMSKÝ, Petr, William WIJNS, Jean FAJADET, Mark DE BELDER, Jiří KNOT, Lars AABERGER, George ANDRIKOPOULOS, Jose Antonio BAZ, Amadeo BETRIU, Marc CLAEYS, Nicolas DANCHIN, Slaveyko DJAMBAZOV, Paul ERNE, Juha HARTIKAINEN, Kurt HUBER, Petr KALA, Milka KLINCEVA, Steen Dalby KRISTENSEN, Peter LUDMAN, Josephina Mauri FERRE, Bella MERKELY, Davor MILICIC, Joao MORAIS, Marko NOC, Grzegorz OPOLSKI, Miodrag OSTOJIC, Dragana RADOVANOVIC, Stefano DE SERVI, Ulf STENESTRAND, Martin STUDENCAN, Marco TUBARO, Zorana VASILJEVIC, Franz WEIDINGER, Adam WITKOWSKI and Uwe ZEYMER. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. European Heart Journal. 2010, vol. 31, No 8, p. 943-957. ISSN 0195-668X. Available from: https://dx.doi.org/10.1093/eurheartj/ehp492.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries
Authors WIDIMSKÝ, Petr (203 Czech Republic, guarantor), William WIJNS (840 United States of America), Jean FAJADET (826 United Kingdom of Great Britain and Northern Ireland), Mark DE BELDER (826 United Kingdom of Great Britain and Northern Ireland), Jiří KNOT (203 Czech Republic), Lars AABERGER (826 United Kingdom of Great Britain and Northern Ireland), George ANDRIKOPOULOS (826 United Kingdom of Great Britain and Northern Ireland), Jose Antonio BAZ (840 United States of America), Amadeo BETRIU (826 United Kingdom of Great Britain and Northern Ireland), Marc CLAEYS (826 United Kingdom of Great Britain and Northern Ireland), Nicolas DANCHIN (826 United Kingdom of Great Britain and Northern Ireland), Slaveyko DJAMBAZOV (826 United Kingdom of Great Britain and Northern Ireland), Paul ERNE (826 United Kingdom of Great Britain and Northern Ireland), Juha HARTIKAINEN (826 United Kingdom of Great Britain and Northern Ireland), Kurt HUBER (826 United Kingdom of Great Britain and Northern Ireland), Petr KALA (203 Czech Republic, belonging to the institution), Milka KLINCEVA (826 United Kingdom of Great Britain and Northern Ireland), Steen Dalby KRISTENSEN (840 United States of America), Peter LUDMAN (826 United Kingdom of Great Britain and Northern Ireland), Josephina Mauri FERRE (826 United Kingdom of Great Britain and Northern Ireland), Bella MERKELY (826 United Kingdom of Great Britain and Northern Ireland), Davor MILICIC (826 United Kingdom of Great Britain and Northern Ireland), Joao MORAIS (826 United Kingdom of Great Britain and Northern Ireland), Marko NOC (826 United Kingdom of Great Britain and Northern Ireland), Grzegorz OPOLSKI (826 United Kingdom of Great Britain and Northern Ireland), Miodrag OSTOJIC (826 United Kingdom of Great Britain and Northern Ireland), Dragana RADOVANOVIC (826 United Kingdom of Great Britain and Northern Ireland), Stefano DE SERVI (826 United Kingdom of Great Britain and Northern Ireland), Ulf STENESTRAND (826 United Kingdom of Great Britain and Northern Ireland), Martin STUDENCAN (826 United Kingdom of Great Britain and Northern Ireland), Marco TUBARO (826 United Kingdom of Great Britain and Northern Ireland), Zorana VASILJEVIC (826 United Kingdom of Great Britain and Northern Ireland), Franz WEIDINGER (826 United Kingdom of Great Britain and Northern Ireland), Adam WITKOWSKI (826 United Kingdom of Great Britain and Northern Ireland) and Uwe ZEYMER (826 United Kingdom of Great Britain and Northern Ireland).
Edition European Heart Journal, 2010, 0195-668X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 10.052
RIV identification code RIV/00216224:14110/10:00058950
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1093/eurheartj/ehp492
UT WoS 000277278900016
Keywords in English Acute myocardial infarction; Reperfusion therapy; Thrombolysis; Primary angioplasty; Europe; Mortality; Incidence
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 4/10/2012 15:22.
Abstract
Patient access to reperfusion therapy and the use of primary percutaneous coronary intervention (p-PCI) or thrombolysis (TL) varies considerably between European countries. The aim of this study was to obtain a realistic contemporary picture of how patients with ST elevation myocardial infarction (STEMI) are treated in different European countries. Methods and results The chairpersons of the national working groups/societies of interventional cardiology in European countries and and results selected experts known to be involved in the national registries joined the writing group upon invitation. Data were collected about the country and any existing national STEMI or PCI registries, about STEMI epidemiology, and treatment in each given country and about PCI and p-PCI centres and procedures in each country. Results from the national and/or regional registries in 30 countries were included in this analysis. The annual incidence of hospital admission for any acute myocardial infarction (AMI) varied between 90-312/100 thousand/year, the incidence of STEMI alone ranging from 44 to 142. Primary PCI was the dominant reperfusion strategy in 16 countries and TL in 8 countries. The use of a p-PCI strategy varied between 5 and 92% (of all STEMI patients) and the use of TL between 0 and 55%. Any reperfusion treatment (p-PCI or TL) was used in 37-93% of STEMI patients. Significantly less reperfusion therapy was used in those countries where TL was the dominant strategy. The number of p-PCI procedures per million per year varied among countries between 20 and 970. The mean population served by a single p-PCI centre varied between 0.3 and 7.4 million inhabitants. In those countries offering p-PCI services to the majority of their STEMI patients, this population varied between 0.3 and 1.1 million per centre. In-hospital mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, for patients treated by TL between 3.5 and 14% and for patients treated by p-PCI between 2.7 and 8%. The time reported from symptom onset to the first medical contact (FMC) varied between 60 and 210 min, FMC-needle time for TL between 30 and 110 min, and FMC-balloon time for p-PCI between 60 and 177 min. Conclusion Most North, West, and Central European countries used p-PCI for the majority of their STEMI patients. The lack of organized p-PCI networks was associated with fewer patients overall receiving some form of reperfusion therapy.
PrintDisplayed: 24/5/2024 05:58